换一批
换一批Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
作者：
Rafee,Talukder [1]
;
Dimitrios,Makrakis [1]
;
Leonidas N,Diamantopoulos [2]
;
Lucia,Carril-Ajuria [3]
;
Daniel,Castellano [3]
;
Ivan,De Kouchkovsky [4]
;
Vadim S,Koshkin [4]
;
Joseph J,Park [5]
;
Ajjai,Alva [5]
;
Mehmet A,Bilen [6]
;
Tyler F,Stewart [7]
;
Rana R,McKay [7]
;
Victor S,Santos [8]
;
Neeraj,Agarwal [8]
;
Jayanshu,Jain [9]
;
Yousef,Zakharia [10]
;
Rafael,Morales-Barrera [11]
;
Michael E,Devitt [12]
;
Michael,Grant [13]
;
Mark P,Lythgoe [13]
;
David J,Pinato [13]
;
Ariel,Nelson [14]
;
Christopher J,Hoimes [15]
;
Evan,Shreck [16]
;
Benjamin A,Gartrell [16]
;
Alex,Sankin [16]
;
Abhishek,Tripathi [17]
;
Roubini,Zakopoulou [18]
;
Aristotelis,Bamias [19]
;
Jure,Murgic [20]
;
Ana,Fröbe [20]
;
Alejo,Rodriguez-Vida [21]
;
Alexandra,Drakaki [22]
;
Sandy,Liu [22]
;
Vivek,Kumar [23]
;
Giuseppe Di,Lorenzo [24]
;
Monika,Joshi [25]
;
Pedro Isaacsson,Velho [26]
;
Lucia Alonso,Buznego [27]
;
Ignacio,Duran [27]
;
Marcus,Moses [28]
;
Pedro,Barata [28]
;
Guru,Sonpavde [29]
;
Evan Y,Yu [30]
;
Jonathan L,Wright [31]
;
Petros,Grivas [32]
;
Ali Raza,Khaki [33]
作者单位：
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
[1]
Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
[2]
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
[3]
Division of Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
[4]
Division of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
[5]
Winship Cancer Institute of Emory University, Atlanta, GA.
[6]
Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
[7]
Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
[8]
Department of Medicine, University of Iowa, Iowa City, IA.
[9]
Division of Oncology, Department of Medicine, University of Iowa, Iowa City, IA.
[10]
Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
[11]
Division of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
[12]
Department of Surgery and Cancer, Imperial College London, London, UK.
[13]
Division of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
[14]
Division of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH; Division of Medical Oncology, Duke University, Durham, NC.
[15]
Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
[16]
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
[17]
Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
[18]
2nd Propaedeutic Dept of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
[19]
Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, School of Dental Medicine, Zagreb, Croatia.
[20]
Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain.
[21]
Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
[22]
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
[23]
Oncology University of Molise and ASL, Salerno, Italy.
[24]
Division of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA.
[25]
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
[26]
Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.
[27]
Deming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
[28]
Genitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
[29]
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
[30]
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Urology, University of Washington, Seattle, WA.
[31]
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: pgrivas@uw.edu.
[32]
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Division of Oncology, Department of Medicine, Stanford University, Palo Alto, CA. Electronic address: alikhaki@stanford.edu.
[33]
主题词
佐剂, 免疫(Adjuvants, Immunologic);投药, 膀胱内(Administration, Intravesical);卡介苗(BCG Vaccine);癌, 移行细胞(Carcinoma, Transitional Cell);人类(Humans);肿瘤复发, 局部(Neoplasm Recurrence, Local);回顾性研究(Retrospective Studies);膀胱肿瘤(Urinary Bladder Neoplasms)
DOI
10.1016/j.clgc.2021.12.012
PMID
35078711
发布时间
2023-04-02
- 浏览0
Clinical genitourinary cancer
Clinical genitourinary cancer
165-175页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
